About this policy
The comment period for the MolDX: Prolaris⢠Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease (LCD) DL37142 began on 02/16/2017 and ended on 04/03/2017. Comments were received from the provider community. The notice period begins on 05/25/2017 and ends 07/09/2017. The LCD becomes final on 07/10/2017.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.